Multiple endocrine neoplasia type 1

References

• Brandi ML, Gagel RF, Angeli A et al. Consensus guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab.86, 5658–5671 (2001).
   PubMed Web of Science ®Google Scholar
• Marx SJ, Simonds WF. Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocr. Rev.26, 615–661 (2005).
   PubMedGoogle Scholar
• Toledo RA, Lourenco DM, Coutinho FL et al. Novel MEN1 germline mutations in Brazilian families with multiple endocrine neoplasia type 1. Clin. Endocrinol. (Oxf.)67, 377–384 (2007).
   PubMedGoogle Scholar
• Wilkinson S, Teh BT, Davey KR, McArdle JP, Young M, Shepherd JJ. Cause of death in multiple endocrine neoplasia type 1. Arch. Surg.128, 683–690 (1993).
   PubMedGoogle Scholar
• Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA Jr, Norton JA. Lethality of multiple endocrine neoplasia type I. World J. Surg.22, 581–586; discussion 586–587 (1998).
   PubMed Web of Science ®Google Scholar
• Lairmore TC, Piersail LD, DeBenedetti MK et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann. Surg.239, 637–645; discussion 645–647 (2004).
   PubMed Web of Science ®Google Scholar
• Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science276, 404–407 (1997).
   PubMed Web of Science ®Google Scholar
• Lemmens I, Van de Ven WJ, Kas K et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum. Mol. Genet.6, 1177–1183 (1997).
   PubMed Web of Science ®Google Scholar
• Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat.29, 22–32 (2008).
   PubMed Web of Science ®Google Scholar
• Larsson C, Nordenskjöld M. Family screening in multiple endocrine neoplasia type 1 (MEN 1). Ann. Med.26, 191–198 (1994).
   PubMed Web of Science ®Google Scholar
• Olufemi SE, Green JS, Manickam P et al. Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. Hum. Mutat.11, 264–269 (1998).
   PubMed Web of Science ®Google Scholar
• Hao W, Skarulis MC, Simonds WF et al. Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J. Clin. Endocrinol. Metab.89, 3776–3784 (2004).
   PubMedGoogle Scholar
• Lourenço DM Jr, Toledo RA, Mackowiak II et al. Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profile. Eur. J. Endocrinol.159, 259–274 (2008).
   PubMedGoogle Scholar
• Guru SC, Goldsmith PK, Burns AL et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc. Natl Acad. Sci. USA95, 1630–1634 (1998).
   PubMed Web of Science ®Google Scholar
• Calender A, Giraud S, Porchet N et al. Clinicogenetic study of MEN1: recent physiopathological data and clinical applications. Study Group of Multiple Endocrine Neoplasia (GENEM). Ann. Endocrinol. (Paris)59, 444–451 (1998).
   PubMedGoogle Scholar
• La P, Desmond A, Hou Z, Silva AC et al. Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression. Oncogene25, 3537–3546 (2006).
   PubMedGoogle Scholar
• La P, Silva AC, Hou Z et al. Direct binding of DNA by tumor suppressor menin. J. Biol. Chem.279, 49045–49054 (2004).
   PubMedGoogle Scholar
• Kim H, Lee JE, Cho EJ, Liu JO, Youn HD. Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase omplex. Cancer Res.63, 6135–6139 (2003).
   PubMedGoogle Scholar
• Yokoyama A, Wang Z, Wysocka J et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell. Biol.24, 5639–5649 (2004).
   PubMed Web of Science ®Google Scholar
• Hughes CM, Rozenblatt-Rosen O, Milne TA et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol. Cell13, 587–597 (2004).
   PubMed Web of Science ®Google Scholar
• Kornberg RD. Chromatin structure: a repeating unit of histones and DNA. Science184, 868–871 (1974).
   PubMed Web of Science ®Google Scholar
• Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell113, 881–889 (2003).
   PubMed Web of Science ®Google Scholar
• Roguev A, Schaft D, Shevchenko A et al. The Saccharomyces cerevisiae Set1 complex includes an Ash2 homologue and methylates histone 3 lysine 4. EMBO J.20, 7137–7148 (2001).
   PubMed Web of Science ®Google Scholar
• Santos-Rosa H, Schneider R, Bannister AJ et al. Active genes are tri-methylated at K4 of histone H3. Nature419, 407–411 (2002).
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell14, 36–46 (2008).
   PubMed Web of Science ®Google Scholar
• Scacheri PC, Davis S, Odom DT et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet.2, e51 (2006).
   PubMedGoogle Scholar
• Agarwal SK, Impey S, McWeeney S et al. Distribution of menin-occupied regions in chromatin specifies a broad role of menin in transcriptional regulation. Neoplasia9, 101–107 (2007).
   PubMedGoogle Scholar
• Shen HC, Rosen JE, Yang LM et al. Parathyroid tumor development involves deregulation of homeobox genes. Endocr. Relat. Cancer15(1), 267–275 (2008).
   PubMedGoogle Scholar
• Varro A, Hemers E, Archer D et al. Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene: role of Rho GTPase and menin. Gastroenterology123, 271–280 (2002).
   PubMedGoogle Scholar
• Shattuck TM, Costa J, Bernstein M, Jensen RT, Chung DC, Arnold A. Mutational analysis of Smad3, a candidate tumor suppressor implicated in TGF-β and menin pathways, in parathyroid adenomas and enteropancreatic endocrine tumors. J. Clin. Endocrinol. Metab.87, 3911–3914 (2002).
   PubMedGoogle Scholar
• Milne TA, Hughes CM, Lloyd R et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl Acad. Sci. USA102, 749–754 (2005).
   PubMed Web of Science ®Google Scholar
• Karnik SK, Hughes CM, Gu X et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc. Natl Acad. Sci. USA102, 14659–14664 (2005).
   PubMed Web of Science ®Google Scholar
• Franklin DS, Godfrey VL, O’Brien DA, Deng C, Xiong Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol. Cell. Biol.20, 6147–6158 (2000).
   PubMed Web of Science ®Google Scholar
• Lin J, Jin R, Zhang B et al. Nucleolar localization of TERT is unrelated to telomerase function in human cells. J. Cell. Sci.121, 2169–2176 (2008).
   PubMed Web of Science ®Google Scholar
• Cerrato A, Parisi M, Santa Anna S et al. Genetic interactions between Drosophila melanogaster menin and Jun/Fos. Dev. Biol.298, 59–70 (2006).
   PubMedGoogle Scholar
• La P, Yang Y, Karnik SK et al. Menin-mediated caspase 8 expression in suppressing multiple endocrine neoplasia type 1. J. Biol. Chem.282, 31332–31340 (2007).
   PubMedGoogle Scholar
• Jin S, Mao H, Schnepp RW et al. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res.63, 4204–4210 (2003).
   PubMed Web of Science ®Google Scholar
• Busygina V, Kottemann MC, Scott KL, Plon SE, Bale AE. Multiple endocrine neoplasia type 1 interacts with forkhead transcription factor CHES1 in DNA damage response. Cancer Res.66, 8397–8403 (2006).
   PubMedGoogle Scholar
• Sukhodolets KE, Hickman AB, Agarwal SK et al. The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene. Mol. Cell. Biol.23, 493–509 (2003).
   PubMedGoogle Scholar
• Schnepp RW, Hou Z, Wang H et al. Functional interaction between tumor suppressor menin and activator of S-phase kinase. Cancer Res.64, 6791–6796 (2004).
   PubMedGoogle Scholar
• Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature387, 733–736 (1997); comment in: Nature387, 654–655 (1997).
   PubMed Web of Science ®Google Scholar
• Heldring N, Pawson T, McDonell D et al. Structural insights into corepressor recognition by antagonist-bound estrogen receptor. J. Biol. Chem.282, 10449–10455 (2007).
   PubMed Web of Science ®Google Scholar
• Dreijerink KM, Höppener JW, Timmers HT, Lips CJ. Mechanisms of disease: multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation. Nat. Clin. Pract. Endocrinol. Metab.2, 562–570 (2006).
   PubMedGoogle Scholar
• Dreijerink KM, Mulder KW, Winkler GS, Höppener JW, Lips CJ, Timmers HT. Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res.66, 4929–4935 (2006).
   PubMedGoogle Scholar
• Karhu A, Aaltonen LA. Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update. Hum. Mol. Genet.16(Spec No 1), R73–R79 (2007).
   PubMed Web of Science ®Google Scholar
• Georgitsi M, Heliövaara E, Paschke R et al. Large genomic deletions in AIP in pituitary adenoma predisposition. J. Clin. Endocrinol. Metab.93, 4146–4151 (2008).
   PubMed Web of Science ®Google Scholar
• Laconi E. The evolving concept of tumor microenvironments. Bioessays29, 738–744 (2007).
   PubMedGoogle Scholar
• Pellegata NS, Quintanilla-Martinez L, Siggelkow H et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl Acad. Sci. USA103, 15558–15563 (2006); erratum in: Proc. Natl Acad. Sci. USA103, 19213 (2006).
   PubMed Web of Science ®Google Scholar
• Van Veelen W, Klompmaker R, Gloerich M et al.p18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma development. Int. J. Cancer124, 339–345 (2009).
   PubMedGoogle Scholar
• Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J. Clin. Endocrinol. Metab.94, 1826–1834 (2009); comment in: J. Clin. Endocrinol. Metab.94, 1518–1520 (2009).
   PubMed Web of Science ®Google Scholar
• Owens M, Stals K, Ellard S, Vaidya B. Germline mutations in the CDKN1B gene encoding p27 Kip1 are a rare cause of multiple endocrine neoplasia type 1. Clin. Endocrinol. (Oxf.)70, 499–500 (2009).
   PubMedGoogle Scholar
• Igreja S, Chahal HS, Akker SA et al. Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clin. Endocrinol. (Oxf.)70, 259–264 (2009).
   PubMedGoogle Scholar
• Gujral TS, van Veelen W, Richardson DS et al. A novel RET kinase-β-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma. Cancer Res.68, 1338–1346 (2008).
   PubMedGoogle Scholar
• Bai F, Pei XH, Nishikawa T, Smith MD, Xiong Y. p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors. Mol. Cell. Biol.27, 1495–1504 (2007).
   PubMedGoogle Scholar
• Roijers JF, de Wit MJ, van der Luijt RB, Ploos van Amstel HK, Höppener JW, Lips CJ. Criteria for mutation analysis in MEN 1-suspected patients: MEN 1 case-finding. Eur. J. Clin. Invest.30, 487–492 (2000).
   PubMedGoogle Scholar
• Norton JA, Venzon DJ, Berna MJ et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger–Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann. Surg.247, 501–510 (2008).
   PubMed Web of Science ®Google Scholar
• Cetani F, Pardi E, Ambrogini E et al. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin. Endocrinol. (Oxf.)64, 146–152 (2006).
   PubMed Web of Science ®Google Scholar
• Prager G, Kalaschek A, Kaczirek K et al. Parathyroidectomy improves concentration and retentiveness in patients with primary hyperparathyroidism. Surgery132, 930–935; discussion: 935–936 (2002).
   PubMedGoogle Scholar
• Bilezikian JP, Potts JT Jr, Fuleihan G-H et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J. Clin. Endocrinol. Metab.87, 5353–5361 (2002).
   PubMedGoogle Scholar
• Bilezikian JP, Khan AA, Potts JT Jr; Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J. Clin. Endocrinol. Metab.94, 335–339 (2009).
   PubMed Web of Science ®Google Scholar
• Khan AA, Bilezikian JP, Potts JT Jr; Guest Editors for the Third International Workshop on Asymptomatic Primary Hyperparathyroidism. The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J. Clin. Endocrinol. Metab.94, 333–334 (2009).
   PubMed Web of Science ®Google Scholar
• Eastell R, Arnold A, Brandi ML et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab.94, 340–350 (2009).
   PubMed Web of Science ®Google Scholar
• Shepherd JJ, Burgess JR, Greenaway TM, Ware R. Preoperative sestamibi scanning and surgical findings at bilateral, unilateral, or minimal reoperation for recurrent hyperparathyroidism after subtotal parathyroidectomy in patients with multiple endocrine neoplasia type 1. Arch. Surg.135, 844–848 (2000).
   PubMedGoogle Scholar
• Malone JP, Srivastava A, Khardori R. Hyperparathyroidism and multiple endocrine neoplasia. Otolaryngol. Clin. North Am.37, 715–736, viii (2004).
   PubMedGoogle Scholar
• Arnalsteen L, Proye C. Surgery of hyperparathyroidism and of its potential recurrence in the MEN I setting. Ann. Chir.128, 706–709 (2003).
   PubMedGoogle Scholar
• Lambert LA, Shapiro SE, Lee JE et al. Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Arch. Surg.140, 374–382 (2005).
   PubMedGoogle Scholar
• Carling T, Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J. Intern. Med.257, 27–37 (2005).
   PubMed Web of Science ®Google Scholar
• Hubbard JG, Sebag F, Maweja S, Henry JF. Subtotal parathyroidectomy as an adequate treatment for primary hyperparathyroidism in multiple endocrine neoplasia type 1. Arch. Surg.141, 235–239 (2006).
   PubMedGoogle Scholar
• Tonelli F, Marcucci T, Fratini G, Tommasi MS, Falchetti A, Brandi ML. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann. Surg.246(6), 1075–1082 (2007).
   PubMedGoogle Scholar
• Hessman O, Stålberg P, Sundin A et al. High success rate of parathyroid reoperation may be achieved with improved localization diagnosis. World J. Surg.32, 774–781; discussion 782–783 (2008).
   PubMedGoogle Scholar
• Faggiano A, Tavares LB, Tauchmanova L et al. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients. Clin. Endocrinol. (Oxf.)69, 756–762 (2008).
   PubMedGoogle Scholar
• Falchetti A, Cilotti A, Vagelli L et al. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nat. Clin. Pract. Endocrinol. Metab.4(6), 351–357 (2008).
   PubMedGoogle Scholar
• Klöppel G, Anlauf M. Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract. Res. Clin. Gastroenterol.19, 507–517 (2005).
   PubMed Web of Science ®Google Scholar
• Zikusoka MN, Kidd M, Eick G, Latich I, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer104, 2292–2309 (2005).
   PubMed Web of Science ®Google Scholar
• Kouvaraki MA, Shapiro SE, Cote GJ et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J. Surg.30, (5) 643–653 (2006).
   PubMedGoogle Scholar
• Levy-Bohbot N, Merle C, Goudet P et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol. Clin. Biol.28, 1075–1081 (2004).
   PubMedGoogle Scholar
• Anlauf M, Schlenger R, Perren A et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am. J. Surg. Pathol.30, 560–574 (2006).
   PubMed Web of Science ®Google Scholar
• Akerstrom G, Hessman O, Hellman P, Skogseid B. Pancreatic tumours as part of the MEN-1 syndrome. Best Pract. Res. Clin. Gastroenterol.19, 819–830 (2005).
   PubMed Web of Science ®Google Scholar
• Thomas-Marques L, Murat A, Delemer B et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancraeticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am. J. Gastroenterol.101, 266–273 (2006).
   PubMed Web of Science ®Google Scholar
• Koopmans KP, de Vries EG, Kema IP et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol.7(9), 728–734 (2006); comment in: Lancet Oncol.7(10), 790–792 (2006).
   PubMedGoogle Scholar
• Koopmans KP, Neels OC, Kema IP et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J. Clin. Oncol.26(9), 1489–1495 (2008).
   PubMed Web of Science ®Google Scholar
• Hellman P, Hennings J, Akerstrom G, Skogseid B. Endoscopic ultrasonography for evaluation of pancreatic tumours in multiple endocrine neoplasia type 1. Br. J. Surg.92, 1508–1512 (2005).
   PubMedGoogle Scholar
• Triponez F, Goudet P, Dosseh D et al. Is surgery beneficial for MEN1 patients with small (≤2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? World J. Surg.30, 654–662 (2006).
   PubMed Web of Science ®Google Scholar
• Tonelli F, Fratini G, Falchetti A, Nesi G, Brandi ML. Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience. J. Intern. Med.257, 38–49 (2005).
   PubMedGoogle Scholar
• Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann. Surg.242, 757–764; discussion 764–766 (2005).
   PubMedGoogle Scholar
• Tonelli F, Fratini G, Nesi G et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann. Surg.244, 61–70 (2006).
   PubMed Web of Science ®Google Scholar
• Falconi M, Bettini R, Boninsegna L et al. Surgical strategy in the treatment of pancreatic neuroendocrine tumors. JOP7, 150–156 (2006).
   PubMedGoogle Scholar
• Libé R, Chanson P. Endocrine tumors of the pancreas (EPTs) in multiple endocrine neoplasia (MEN1): up-date on prognostic factors, diagnostic procedures and treatment. Ann. Endocrinol. (Paris)68(Suppl. 1), 1–8 (2007); erratum in: Ann. Endocrinol. (Paris)69, 459–460 (2008).
   PubMedGoogle Scholar
• Viola KV, Sosa JA. Current advances in the diagnosis and treatment of pancreatic endocrine tumors. Curr. Opin. Oncol.17, 24–27 (2005).
   PubMed Web of Science ®Google Scholar
• Hoffmann KM, Gibril F, Entsuah LK, Serrano J, Jensen RT. Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett’s esophagus. J. Clin. Endocrinol. Metab.91, 204–212 (2006).
   PubMed Web of Science ®Google Scholar
• Geerdink EA, Van der Luijt RB, Lips CJ. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? Eur. J. Endocrinol.149, 577–582 (2003).
   PubMedGoogle Scholar
• Imamura M, KomotoI, Ota S. Changing treatment strategy for gastrinoma in patients with ZES. World J. Surg.30, 1–11 (2006).
   PubMed Web of Science ®Google Scholar
• Tomassetti P, Campana D, Piscitelli L et al. Treatment of Zollinger–Ellison syndrome. World J. Gastroenterol.21, 5423–5432 (2005).
   Google Scholar
• Granberg D, Jacobsson H, Oberg K, Gustavsson J, Lehtihet M. Regression of a large malignant gastrinoma on treatment with sandostatin LAR: a case report. Digestion77, 92–95 (2008).
   PubMedGoogle Scholar
• Wang HS, Oh DS, Ohning GV, Pisegna JR. Cyto-reduction of neuroendocrine tumours using Sandostatin LAR in combination with Infergen: results of a case series. J. Pharm. Pharmacol.58, 1623–1628 (2006).
   PubMedGoogle Scholar
• Kauhanen S, Seppänen M, Minn H et al. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients J. Clin. Endocrinol. Metab.92, 1237–1244 (2007).
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Smit JW, Pereira AM, Frölich M, Romijn JA, Roelfsema F. Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Pituitary10, 237–249 (2007).
   PubMedGoogle Scholar
• Ferolla P, Faggiano A, Mansueto G et al. The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J. Endocrinol. Invest.31, 277–286 (2008).
   PubMed Web of Science ®Google Scholar
• Rix M, Hertel NT, Nielsen FC et al. Cushing’s disease in childhood as the first manifestation of multiple endocrine neoplasia syndrome type 1. Eur. J. Endocrinol.151, 709–715 (2004).
   PubMedGoogle Scholar
• Stratakis CA, Schussheim DH, Freedman SM et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab.85, 4776–4780 (2000).
   PubMed Web of Science ®Google Scholar
• Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary8, 3–6 (2005).
   PubMedGoogle Scholar
• Vierimaa O, Georgitsi M, Lehtonen R et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science312, 1228–1230 (2006).
   PubMed Web of Science ®Google Scholar
• Beckers A, Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur. J. Endocrinol.157, 371–382 (2007).
   PubMed Web of Science ®Google Scholar
• Benito M, Asa SL, Livolsi VA, West VA, Snyder PJ. Gonadotroph tumor associated with multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab.90, 570–574 (2005).
   PubMedGoogle Scholar
• Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin. Endocrinol. (Oxf.)70, 104–108 (2009).
   PubMed Web of Science ®Google Scholar
• Kars M, Pereira AM, Bax JJ, Romijn JA. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur. J. Endocrinol.159(4), 363–367 (2008).
   PubMed Web of Science ®Google Scholar
• Higham C, Chung T, Lawrance J, Drake W, Trainer P. Long term experience of pegvisomant therapy as a treatment for acromegaly. Clin. Endocrinol. (Oxf.), DOI: 10.1111/j.1365-2265.2008.03469.x (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Bush ZM, Vance ML. Management of acromegaly: is there a role for primary medical therapy? Rev. Endocr. Metab. Disord.9, 83–89 (2008).
   PubMed Web of Science ®Google Scholar
• Boscaro M, Ludlam WH, Atkinson B et al. Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, Phase II trial. J. Clin. Endocrinol. Metab.94, 115–122 (2009).
   PubMed Web of Science ®Google Scholar
• Schaefer S, Shipotko M, Meyer S et al. Natural course of small adrenal lesions in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Eur. J. Endocrinol.158, 699–704 (2008).
   PubMedGoogle Scholar
• Whitley SA, Moyes VJ, Park KM et al. The appearance of the adrenal glands on computed tomography in multiple endocrine neoplasia type 1. Eur. J. Endocrinol.159, 819–824 (2008).
   PubMedGoogle Scholar
• Waldman J, Bartsch DK, Kann PH, Fendrich V, Rothmund M, Langer P. Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening. Langenbecks Arch. Surg.392, 437–443 (2007).
   PubMedGoogle Scholar
• Langer P, Cupisti K, Bartsch DK et al. Adrenal involvement in multiple endocrine neoplasia type 1. World J. Surg.26, 891–896 (2002).
   PubMedGoogle Scholar
• Teh BT, Zedenius J, Kytölä S et al. Thymic carcinoids in multiple endocrine neoplasia type 1. Ann. Surg.228, 99–105 (1998).
   PubMed Web of Science ®Google Scholar
• Goudet P, Murat A, Cardot-Bauters C et al. The members of the GTE network. Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J. Surg.33(6), 1197–1207 (2009).
   PubMedGoogle Scholar
• Ferolla P, Falchetti A, Filosso P et al. Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. J. Clin. Endocrinol. Metab.90, 2603–2609 (2005).
   PubMedGoogle Scholar
• Gibril F, Chen YJ, Schrump DS et al. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab.88, 1066–1081 (2003).
   PubMedGoogle Scholar
• Lim LC, Tan MH, Eng C, Teh BT, Rajasoorya RC. Thymic carcinoid in multiple endocrine neoplasia 1: genotype–phenotype correlation and prevention. J. Intern. Med.259, 428–432 (2006).
   PubMedGoogle Scholar
• Takagi J, Otake K, Morishita M et al. Multiple endocrine neoplasia type I and Cushing’s syndrome due to an aggressive ACTH producing thymic carcinoid. Intern. Med.45, 81–86 (2006).
   PubMedGoogle Scholar
• Sachithanandan N, Harle RA, Burgess JR. Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1. Cancer103, 509–515 (2005).
   PubMedGoogle Scholar
• Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger–Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery136, 1267–1274 (2004).
   PubMed Web of Science ®Google Scholar
• Tham E, Grandell U, Lindgren E, Toss G, Skogseid B, Nordenskjöld M. Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. J. Clin. Endocrinol. Metab.92, 3389–3395 (2007).
   PubMedGoogle Scholar
• Owens M, Ellard S, Vaidya B. Analysis of gross deletions in the MEN1 gene in patients with multiple endocrine neoplasia type 1. Clin. Endocrinol. (Oxf.)68, 350–354 (2008).
   PubMed Web of Science ®Google Scholar
• Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am. J. Med.16, 363–371 (1954).
   PubMed Web of Science ®Google Scholar
• Trump D, Farren B, Wooding C et al. Clinical studies of multiple endocrine neoplasia type 1(MEN-1). Q. J. Med.89, 653–669 (1996).
   Google Scholar
• Ballard HS, Frame B, Hartstock RJ. Familial multiple endocrine adenoma–peptic ulcer complex. Medicine43, 481–516 (1968).
   Google Scholar
• Pipeleers-Marichal M, Somers G, Willems G et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger–Ellison syndrome. N. Engl. J. Med.322, 723–727 (1990).
   PubMed Web of Science ®Google Scholar
• Skogseid B, Erikson B, Lundqvist G et al. Multiple endocrine neoplasia type 1: a 10 years prospective screening study in four kindreds. J. Clin. Endocrinol. Metab.73, 281–287 (1991).
   PubMed Web of Science ®Google Scholar
• Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann. Int. Med.129, 484–494 (1998).
   PubMed Web of Science ®Google Scholar
• Skogseid B, Larsson C, Lindgren PG et al. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab.75, 76–81 (1992).
   PubMed Web of Science ®Google Scholar
• Vasen HF, Lamers CB, Lips CJ. Screening for the multiple endocrine neoplasia syndrome type 1: a study of 11 kindreds in the Netherlands. Arch. Int. Med.149, 2717–2722 (1989).
   PubMed Web of Science ®Google Scholar
• Öberg K, Skogseid B, Eriksson B. Multiple endocrine neoplasia type 1 (MEN-1): clinical, biochemical and genetical investigations. Acta Oncol.28, 383–387 (1989).
   PubMed Web of Science ®Google Scholar
• Carty SE, Helm AK, Amico JA et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery124, 1106–1114 (1998).
   PubMedGoogle Scholar
• Duh QY, Hybarger CP, Geist R et al. Carcinoids associated with multiple endocrine neoplasia syndromes. Am. J. Surg.154, 142–148 (1987).
   PubMed Web of Science ®Google Scholar
• Teh BT, McArdle J, Chan SP et al. Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1. Medicine76, 21–29 (1997).
   PubMed Web of Science ®Google Scholar
• Darling TN, Skarulis MC, Steinberg SM, Marx SJ, Spiegel AM, Turner M. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch. Dermatol.133, 853–857 (1997).
   PubMedGoogle Scholar
• Vortmeyer AO, Lubensky IA, Skarulis M et al. Multiple endocrine neoplasia type 1: atypical presentation, clinical course, and genetic analysis of multiple tumors. Mod. Pathol.12, 919–924 (1999).
   PubMedGoogle Scholar
• Heppner C, Bilimoria KY, Agarwal SK et al. The tumor suppressor protein menin interacts with NF-κB proteins and inhibits NF-κB-mediated transactivation. Oncogene20, 4917–4925 (2001).
   PubMed Web of Science ®Google Scholar
• Lemmens IH, Forsberg L, Pannett AA et al. Menin interacts directly with the homeobox-containing protein Pem. Biochem. Biophys. Res. Commun.286, 426–431 (2001).
   PubMedGoogle Scholar
• Kaji H, Canaff L, Lebrun JJ, Goltzman D, Hendy GN. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type β signaling. Proc. Natl Acad. Sci. USA98, 3837–3842 (2001).
   PubMed Web of Science ®Google Scholar
• Chen G, A J, Wang M et al. Menin promotes the Wnt signaling pathway in pancreatic endocrine cells. Mol. Cancer Res.6, 1894–1907 (2008).
   PubMedGoogle Scholar
• Lopez-Egido J, Cunningham J, Berg M, Oberg K, Bongcam-Rudloff E, Gobl A. Menin’s interaction with glial fibrillary acidic protein and vimentin suggests a role for the intermediate filament network in regulating menin activity. Exp. Cell Res.278, 175–183 (2002).
   PubMedGoogle Scholar
• Ohkura N, Kishi M, Tsukada T, Yamaguchi K. Menin, a gene product responsible for multiple endocrine neoplasia type 1, interacts with the putative tumor metastasis suppressor nm23. Biochem. Biophys. Res. Commun.282, 1206–1210 (2001).
   PubMed Web of Science ®Google Scholar
• Yan J, Yang Y, Zhang H et al. Menin interacts with IQGAP1 to enhance intercellular adhesion of β-cells. Oncogene28, 973–982 (2009).
   PubMedGoogle Scholar
• Obungu VH, Lee Burns A, Agarwal SK, Chandrasekharapa SC, Adelstein RS, Marx SJ. Menin, a tumor suppressor, associates with nonmuscle myosin II-A heavy chain. Oncogene22, 6347–6358 (2003).
   PubMedGoogle Scholar
• Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg. Oncol.12, 153–172 (2003).
   PubMed Web of Science ®Google Scholar
• Kidd M, Modlin IM, Black JW, Boyce M, Culler M. A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation. Regul Pept.143, 109–117 (2007).
   PubMed Web of Science ®Google Scholar
• Dockray GJ. Clinical endocrinology and metabolism. Gastrin. Best Pract. Res. Clin. Endocrinol. Metab.18, 555–568 (2004).
   PubMedGoogle Scholar
• Schubert ML. Hormonal regulation of gastric acid secretion. Curr. Gastroenterol. Rep.10, 523–527 (2008).
   PubMedGoogle Scholar
• Dufner MM, Kirchhoff P, Remy C et al. The calcium-sensing receptor acts as a modulator of gastric acid secretion in freshly isolated human gastric glands. Am. J. Physiol. Gastrointest. Liver Physiol.289, G1084–G1090 (2005).
   Google Scholar